Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.215
Journals
Pharmaceuticals
Special Issues
Personalized Medicine
share announcement

Special Issue "Personalized Medicine"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 December 2009) | Viewed by 49485

Special Issue Editors

Prof. Dr. Munir Pirmohamed

E-Mail
Guest Editor
NHS Chair of Pharmacogenetics, MRC Centre for Drug Safety Sciences,Department of Pharmacology, The University of Liverpool, Ashton Street, Liverpool L69 3GE, UK
Interests: pharmacogenomics; stratified medicines; drug safety; clinical pharmacology; alcohol dependency; alcoholic liver disease
Dr. Graeme J. Sills

E-Mail
Guest Editor
Division of Neurological Science, University of Liverpool, Clinical Sciences Centre for Research & Education, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK
Interests: pharmacogenomics; metabonomics; epilepsy; antiepileptic drugs; mechanisms of action; drug metabolism; drug resistance

Special Issue Information

Dear Colleagues,

Inter-individual variation in drug response is a major hurdle to successful disease management. Some patients will respond well to the introduction of a new medication, others will achieve little or no benefit, some will get worse, many will not tolerate the new drug and an unfortunate few may experience a severe adverse reaction. This uncertainty about the outcome of treatment is a reflection of the empiricism which remains in modern medicine and which has significant social and economic consequences. The concept of personalized medicine is one in which biological information about an individual is used to optimise the diagnosis and management of their disease. It holds promise for the rational use of therapy and the avoidance of poor and potentially life-threatening outcomes. After many years of wishful predictions, we now stand on the cusp of an era of personalized medicine, with applications already emerging in several areas of clinical care and others expected to bear fruit in due course. This is in part due to the success of the Human Genome Project, an improved understanding of human biology, and the widening availability of technologies to support systems biology research. This special issue of Pharmaceuticals will highlight ongoing investigations and recent developments in the pursuit of personalized medicine in several key therapeutic arenas, with particular emphasis on genetic contributors to variation in drug responsiveness.

Graeme J. Sills, Ph. D.
Prof. Dr. Munir Pirmohamed
Guest Editors

Keywords

  • pharmacogenomics
  • pharmacogenetics
  • pharmacoproteomics
  • pharmacometabolomics
  • personalized medicine
  • combined diagnostics and therapeutics
  • systems biology
  • individualized treatment
  • therapeutics

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

get_app
Article
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
by
Marja-Liisa Dahl
and
Pharmaceuticals 2010, 3(4), 782-794; https://doi.org/10.3390/ph3040782 - 24 Mar 2010
Cited by 6 | Viewed by 10633
Abstract
Increasing evidence for the role of pharmacogenetics in treatment resistance to the antiplatelet agent clopidogrel has been gained during the last years. Apart from CYP2C19 genetic polymorphisms, nongenetic factors, particularly drug-drug interactions, age and other clinical characteristics influence the interindividual variability in clopidogrel [...] Read more.
Increasing evidence for the role of pharmacogenetics in treatment resistance to the antiplatelet agent clopidogrel has been gained during the last years. Apart from CYP2C19 genetic polymorphisms, nongenetic factors, particularly drug-drug interactions, age and other clinical characteristics influence the interindividual variability in clopidogrel response to varying degrees. The present article reviews the so far accumulated evidence on the role of pharmacogenetic traits influencing CYP-activity as determinants of the antiplatelet response to clopidogrel, and its clinical implications. The genetic variation in CYP2C19 activity seems to influence short- and long-term antithrombotic effects of clopidogrel to a substantial extent. Prediction models for clopidogrel non-responsiveness that include CYP2C19 genotyping together with relevant non-genetic risk factors are needed to be verified for their potential benefit in individualization of antithrombotic therapy. Full article
(This article belongs to the Special Issue Personalized Medicine)
►▼ Show Figures

Figure 1

Review

Jump to: Research

get_app
Review
Drug Induced Hypersensitivity and the HLA Complex
by
Ana Alfirevic
and
Pharmaceuticals 2011, 4(1), 69-90; https://doi.org/10.3390/ph4010069 - 23 Dec 2010
Cited by 31 | Viewed by 8384
Abstract
Drug-induced hypersensitivity reactions are of major concern and present a burden for national healthcare systems due to their often severe nature, high rate of hospital admissions and high mortality. They manifest with a wide range of symptoms and signs, and can be initiated [...] Read more.
Drug-induced hypersensitivity reactions are of major concern and present a burden for national healthcare systems due to their often severe nature, high rate of hospital admissions and high mortality. They manifest with a wide range of symptoms and signs, and can be initiated by a wide range of structurally diverse chemical compounds. The pathophysiological mechanisms underlying hypersensitivity reactions are not well understood, but it is thought that they are immune mediated. MHC region on Chromosome 6 contains many genes with immune function. Classical MHC molecules are highly polymorphic cell surface glycoproteins whose function is to present peptide antigens to T cells. In addition to conferring protection from some diseases, HLA alleles are also associated with an increased risk of other diseases, including drug-induced hypersensitivity. Pharmacogenetic approach to predict the risk of drug-induced hypersensitivity has been established for several drugs. We will discuss the progress of hypersensitivity pharmacogenetics over the last few years and focus on current efforts of the international community to develop consortia which aim to standardize disease phenotypes and to identify affected individuals through international collaborations. In addition, we will discuss the clinical utility of HLA typing as predictive or diagnostic testing for drug-induced hypersensitivity. Full article
(This article belongs to the Special Issue Personalized Medicine)
get_app
Review
The Pharmacogenomics of Anti-Hypertensive Therapy
by
Sandosh Padmanabhan
,
Laura Paul
and
Anna F. Dominczak
Pharmaceuticals 2010, 3(6), 1779-1791; https://doi.org/10.3390/ph3061779 - 01 Jun 2010
Cited by 11 | Viewed by 10766
Abstract
Hypertension is a major public health problem, but measures to reduce blood pressure and thus cardiovascular risk are complicated by the high prevalence of treatment resistance, despite the availability of multiple drugs. Drug side-effects contribute considerably to suboptimal blood pressure control. Clinicians must [...] Read more.
Hypertension is a major public health problem, but measures to reduce blood pressure and thus cardiovascular risk are complicated by the high prevalence of treatment resistance, despite the availability of multiple drugs. Drug side-effects contribute considerably to suboptimal blood pressure control. Clinicians must often rely on empirical methods to match patients with effective drug treatment. Hypertension pharmacogenomics seeks to find genetic predictors of response to drugs that lower blood pressure and to translate this knowledge into clinical practice. In this review we summarise the current status of hypertension pharmacogenetics from monogenic hypertension to essential hypertension and discuss the issues that need to be considered in a hypertension pharmacogenomic study. Full article
(This article belongs to the Special Issue Personalized Medicine)
►▼ Show Figures

Figure 1

get_app
Review
Beyond Genetics—Stratified and Personalised Medicines Using Multiple Parameters
by
Richard Peck
and
Patrick Smith
Pharmaceuticals 2010, 3(5), 1637-1651; https://doi.org/10.3390/ph3051637 - 25 May 2010
Cited by 4 | Viewed by 9199
Abstract
Prescribers have been practicing stratified medicine for many years. Patient characteristics, usually non-genetic, including age, comorbidities and concomitant medications are taken into account when deciding which drug to prescribe. In addition, the majority of drugs require dose adjustments across patient subgroups, usually determined [...] Read more.
Prescribers have been practicing stratified medicine for many years. Patient characteristics, usually non-genetic, including age, comorbidities and concomitant medications are taken into account when deciding which drug to prescribe. In addition, the majority of drugs require dose adjustments across patient subgroups, usually determined by non-genetic differences between the subgroups. Whilst pharmacogenetics hold promise for enhancing treatment stratification and even treatment individualisation, non-genetic factors will continue to be very important. Both non-genetic and genetic factors must be considered to improve understanding and quantification of the variability in treatment outcomes and to guide stratification and targeting of patient subgroups to the right drug and also to the right range of doses within that subgroup. Development of stratified medicines must consider non-genetic as well as genetic factors and, where appropriate, include stratification through optimising the dose for each patient or subgroup as well as by choosing the drug most likely to deliver efficacy to that patient or group. Full article
(This article belongs to the Special Issue Personalized Medicine)
►▼ Show Figures

Figure 1

get_app
Review
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
by
Roberta Ferraldeschi
and
William G. Newman
Pharmaceuticals 2010, 3(4), 1122-1138; https://doi.org/10.3390/ph3041122 - 15 Apr 2010
Cited by 14 | Viewed by 10116
Abstract
Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly [...] Read more.
Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy. Full article
(This article belongs to the Special Issue Personalized Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop